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ABSTRACT: This study investigates the mechanism of protein particle formation during ultrafiltration/diafiltration (UF/DF), finding that
agitation drives particle formation by promoting protein-interface adsorption and desorption. Low conductivity and the presence of
surfactant reduced the level of particle formation in small-scale stirring studies, and the same trends were observed in pumping and UF/DF.
Polysorbate 80 (PS80) and hydroxypropyl--cyclodextrin (HPCD) reduced particle formation in UF/DF by factors of 15 and 4, respectively.
Measurements of conformational stability, colloidal stability, and surface tension demonstrated that PS80 protects against particle formation
by preventing protein-interface adsorption, low conductivity improves the colloidal stability of the protein, and the mechanism of action
of HPCD remains unclear. This work demonstrates that interfacial adsorption–desorption of the protein during UF/DF is the principal
cause of particle formation, that the level of surfactant-free particle formation depends on the colloidal stability of the protein, and that
the inclusion of surfactant greatly reduces in-process particle formation during UF/DF. C© 2014 The Authors. Journal of Pharmaceutical
Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:862–869, 2014
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INTRODUCTION
The complex molecular architecture of protein pharmaceuti-
cals leads to a propensity toward the formation of aggregates
ranging from dimers to micron-sized particles. Although parti-
cles typically account for a small mass percentage and often do
not impact drug potency, protein aggregates and particles may
elicit immunogenic responses.1–3 Therefore, controlling protein
particle formation is a major focus in the development of bio-
pharmaceuticals.
There are multiple pathways to protein particle formation.4
In the simplest pathway, an aggregation-prone protein forms
higher order oligomers that in some cases grow to micron-sized
particles. Proteins may also undergo conformational changes
that increase their susceptibility to particle formation, either
because of intrinsic conformational instability or in response
to an external stress. Proteins adhere to a wide range of sur-
faces, including air–liquid and liquid–solid interfaces, and the
accumulation of proteins on these surfaces can lead to particle
formation, in some cases following a surface-induced conforma-
tional change. Foreign particles can also serve as nucleation
sites for the formation of protein particles.
The growing understanding of these pathways to particle for-
mation has led to a successful approach to mitigating particle
formation in which the formulation composition is selected to
maximize the conformational stability of the protein and pro-
vide interfacial protection. The purification process must also
be optimized to remove potential particle-nucleating impuri-
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ties. However, the purification process itself presents a variety
of stresses that can lead to in-process particle formation. Al-
though in-process particle formation is sometimes disregarded
with the expectation that these particles will be removed by
filtration, we argue that it is essential to understand and limit
in-process particle formation to establish a well-controlled pro-
cess, reduce the particle burden for filtration, and reduce the
risk that prefiltration stresses could lead to postfiltration par-
ticle formation.
Multiple authors have noted the formation of protein aggre-
gates during ultrafiltration/diafiltration (UF/DF) operation,5–7
and we have observed millions of micron-sized particles per
milliliter in the UF/DF products of multiple proteins prior to fi-
nal filtration. The complexity of the UF/DF unit operation leads
to several hypotheses for the principal mechanism of UF/DF-
induced particle formation: (1) shear stress or other character-
istics of the fluid flow, (2) impurities leached into the product
stream from contact surfaces during extended periods of re-
circulation, (3) interfacial interactions, and (4) pump-specific
stresses such as cavitation and tubing spallation.
First, we consider the possibility of shear stress-driven parti-
cle formation. Many studies have demonstrated that exposing a
protein to shear stress can lead to protein aggregation, although
the mechanism of this effect remains unclear. Some argue that
the shear stress itself induces a conformational change that re-
sults in protein aggregation,8 whereas others propose that the
associated fluid flow increases reactive collisions in the bulk or
facilitates protein transport to and from aggregation-inducing
interfaces.9 Early studies on enzyme activity reported a signif-
icant reduction in activity upon shear,10 suggesting that shear
disrupted the structure and thus the function of the enzymes
under study, but shear did not induce a conformational change
in cytochrome C.11 Another set of studies showed that shear
by a rotating disk led to protein aggregation with the amount
of monomer loss depending on the shear rate,12 that this ag-
gregation did not involve covalent modifications, and that the
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level of aggregation was reduced by the addition of surfactant
and increased by an increase in the surface roughness of the ro-
tating disk.13 These results suggest that shear induces protein
aggregation by enhancing the transport of the protein to and
from interfaces rather than by directly affecting the protein.
This agrees with other studies showing that shear alone does
not lead to the aggregation of monoclonal antibodies,14 that
shear induces aggregation through the air–liquid interface,15
and that polysorbate prevents antibody precipitation under
shear.16 One study suggested that altering the flow parameters
of UF/DF operation could limit particle formation by changing
the shear stress experienced by the protein.7 Although the mod-
ified parameters successfully limited aggregation and particle
formation, the maximal reduction was only two-fold, suggest-
ing that shear itself may not be the main driver of particle
formation in UF/DF.
A second pathway to protein particle formation that may
be involved in UF/DF-induced particle formation is nucle-
ation on foreign particles present in solution, also referred
to as heterogeneous nucleation.4,17 For example, filling pump-
induced particle formation was related to the shedding of steel
nanoparticles that acted as nucleation sites for protein particle
formation.18 In another case, protein precipitation was induced
by soluble tungsten, an impurity that can be present in pre-
filled syringes.19 During UF/DF operation, the repeated flow
of the protein solution over various materials including the
membrane, tubing, and retentate tank could result in impuri-
ties leaching into the product stream and promoting particle
formation, with the portion of the tubing that is repeatedly
stressed by the pump head as a particularly likely source of
such impurities.
Third, proteins come into contact with a variety of inter-
faces during UF/DF operation, including solid–liquid and air–
liquid interfaces, and interfacial adsorption could lead to pro-
tein particle formation. Protein-interface adsorption is often
based on hydrophobic interactions, but electrostatic interac-
tions also play an important role.4 Surface-induced particle
formation may involve a conformational rearrangement of the
protein to maximize its area of interaction with the surface or
to minimize the energy of that interaction,4,20 or the surface
may instead promote protein–protein association without any
conformational event.16 Surfactants in biopharmaceutical for-
mulations protect against particle formation by competing with
protein molecules for interfacial adsorption, preventing protein
adsorption to interfaces.21 For example, surfactants protect pro-
teins from exposure to the air–liquid interface in static vials
during long-term storage, and also provide protection during
short time-scale perturbations of that interface such as during
product shipping. Surfactants can also exert effects through di-
rect interactions with the protein.22 Proteins commonly adsorb
on solid interfaces, and solid materials such as stoppers and
tubing have been implicated in particle formation.23,24 UF/DF
operation presents multiple solid interfaces (tank, tubing, and
membrane surfaces) as well as an air–liquid interface, suggest-
ing that interfacial interactions could play a role in UF/DF-
driven particle formation.
Fourth, pump-specific stresses are often implicated in pro-
tein particle formation, and pump-driven particle forma-
tion has been suggested as a route to particle formation
in UF/DF.6 Pumping itself represents a complex stress en-
compassing shear stress, surface interactions, potential intro-
duction of impurities through leaching or tubing spallation,
and potential cavitation. Filling pumps have been implicated
in protein particle formation,25 and pump-induced cavitation
has been suggested as the cause of UF/DF-induced protein
aggregation.6
The goal of this study is to identify which of the possible
mechanisms described above is the dominant factor in protein
particle formation during UF/DF operation: shear stress, im-
purities, interfacial interactions, or some combination of these
factors present in the pump or the overall unit operation. We ac-
complish this by breaking the UF/DF unit operation into its con-
stituent parts, examining the effects of solution conditions and
additives on agitation-induced particle formation, and studying
the biophysical properties of the protein in these solutions. The
results of this work indicate a primarily interfacially driven
mechanism of particle formation in UF/DF and suggest several
viable particle mitigation strategies.
MATERIALS AND METHODS
Proteins
This study used the four in-house IgG molecules mAb A, B, C,
and D (A, B, and C are IgG 1 and D is IgG 2), and the pro-
teins lysozyme, ovalbumin, and "-chymotrypsinogen (Sigma,
St. Louis, Missouri). The proteins were dialyzed or diafiltered
into the appropriate buffers for experimentation, and in all
cases were filtered through a 0.22 :m filter immediately prior
to the experiment. Except where noted, data in this manuscript
were collected at a protein concentration of 5 mg/mL.
Particle Measurement
For all experiments, particle formation was monitored us-
ing Micro-Flow ImagingTM (model DPA-4200; Protein Simple,
Santa Clara, California). Undiluted 1 mL samples were loaded
on the instrument, and 600 :L were measured (or >106 par-
ticles) at a flow rate of 150 :L/min. The data reported here
represent the total number of particles per milliliter with an
estimated circular diameter of more than 1 :m (1 :m is the
lower limit of particle size that can be detected by this instru-
ment).
UF/DF Recirculation
Ultrafiltration/diafiltration recirculation experiments were
conducted using a semiautomated tangential flow filtration
(TFF) system including a tandem peristaltic pump (SciLog,
Madison, Wisconsin) and a MinimateTM TFF capsule with a
50 cm2 OmegaTM (modified polyethersulfone) membrane (Pall,
Port Washington, New York). All UF/DF experiments used a 1
foot section of STA-PURE R© tubing (Thermo Scientific, Waltham,
Massachusetts) at the pump head and platinum-cured silicon
tubing elsewhere. To ensure that the mixing in the retentate
tank was consistent across experiments, the retentate tank was
placed on a magnetic stir plate (Corning PC-410D; Corning,
New York) and stirred at 300 rpm. In recirculation experiments,
100 mL of 5 mg/mL mAb was placed in the retentate vessel and
both the retentate and permeate were routed back to the tank
to maintain a constant volume throughout the process.
Stirring in Vials
Small-scale stirring experiments were conducted with 3 mL of
protein solution in 3 mL glass vials (Schott AG #6800-0316,
Mainz, Germany) with headspace, with Teflon stoppers (West
DOI 10.1002/jps.23861 Callahan, Stanley, and Li, JOURNAL OF PHARMACEUTICAL SCIENCES 103:862–869, 2014
864 RESEARCH ARTICLE – Pharmaceutical Biotechnology
Pharmaceutical, Exton, Pennsylvania) and 7 × 2 mm PTFE
magnetic stir bars (VWR, Radnor, Pennsylvania), stirred at 250
rpm on a 15-position magnetic stir plate (Thermo Scientific).
Pumping
Pumping experiments were conducted using a Masterflex R© L/S
Easyflex II peristaltic pump (Cole Parmer, Vernon Hills, Illi-
nois) at 50 mL/min. A 1 foot section of STA-PURE R© tubing
(Thermo Scientific) at the pump head was flanked by two 1.5
feet sections of size 16 Masterflex R© platinum-cured silicone tub-
ing, and 40 mL of 5 mg/mL mAb was pumped from and returned
to a 50 mL centrifuge tube without stirring.
Dynamic Scanning Calorimetry
Dynamic scanning calorimetry (DSC) was performed using a
MicroCal VP-Capillary DSC (GE Healthcare, Piscataway, New
Jersey). After 0.22 :m filtration, 1 mg/mL mAb solutions in
10 mM histidine, pH 6.0, were heated from 20◦C to 95◦C at
90◦C/h. Tm1 and Tm2 values corresponding to unfolding were
determined as the peak temperatures of the Cp versus T graph.
Dynamic Light Scattering
Dynamic light scattering (DLS) of 0.22 :m filtered mAb solu-
tions from 1 to 10 :M in 10 mM histidine, pH 6.0, was carried
out using a DynaPro R© Plate Reader (Wyatt Technology, Santa
Barbara, California). Diffusivity values based on a cumulants
fit were averaged across six wells. Three independent dilution
series were tested for each condition, and a linear regression
of the average D versus [mAb] data was performed in Graph-
Pad Prism (GraphPad Software, La Jolla, California). The kD
was determined by dividing the slope of the best-fit line by the
y-intercept.26
Surface Tensiometry
The surface tension of 0.22 :m filtered 5 mg/mL mAb solutions
in 10 mM histidine, pH 6.0, was determined using a K100C sur-
face tensiometer (Kruss, Hamburg, Germany) and a Wilhelmy
plate. The reported values represent the equilibrium surface
tension after 5 h of measurements, with data points collected
every 60 s.
UF/DF Concentration and Filterability Measurement
In bench-scale UF/DF concentration experiments, approxi-
mately 5 g mAb was concentrated from roughly 5 to 40 mg/mL,
diafiltration was conducted at 40 mg/mL for six diavolumes,
and then a final concentration was performed to 120 mg/mL.
These experiments were conducted using an 88 cm2 Pellicon 3
Biomax polyethersulfone membrane (Millipore, Billerica, Mas-
sachusetts). After bench-scale UF/DF concentration, the fil-
terability of the final solution was measured by diluting the
concentrated solution to the target protein concentration of
100 mg/mL and then conducting constant pressure filtration
through a 0.22 :m PES filter using a FilterTec Normal Flow
Filtration system (SciLog). As a linear relationship was ob-
served between time/volume and time, the gradual pore plug-
ging model was applied ( tV = At + B, or tV = 1Vmax + 1Qi , where
t is time, V is volume filtered at time t, Vmax represents the
maximum volume that can be filtered at infinite time, and Qi
is the instantaneous initial flow).27 Thus, the Vmax was calcu-
lated as the inverse of the slope of the time/volume versus time
plot, which was then divided by the surface area of the filter to
obtain filterability (L/m2).
Statistical Analysis
Statistical comparisons were carried out in GraphPad Prism
(GraphPad Software) by performing an ANOVA followed by a
t-test. p < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
On the basis of a previous report that particle formation dur-
ing UF/DF operation could be controlled by the transmembrane
pressure (TMP) and feed flow rate because of the relation-
ship between these parameters and the shear stress across the
UF/DF membrane,7 we explored the effect of these parameters
on particle formation in the UF/DF of mAb A. In these experi-
ments, 100 mL of mAb A at 5 mg/mL were recirculated in the
UF/DF unit over 4 h while the solution in the retentate vessel
was mixed with a stir bar. Although Figure1a does demonstrate
variability among experiments with different combinations of
feed flow and TMP, no consistent trend in particle formation
was observed with respect to feed flow rate or TMP.
In a separate experiment, the retentate tank was discon-
nected from the rest of the unit and particle formation was
monitored in response to stirring alone. As shown in Figure 1b,
stirring in the retentate tank alone induced particle formation
at a similar rate as UF/DF recirculation with stirring. The de-
crease in the rate of particle formation at later time points in
Figure 1. Monitoring protein particle formation during UF/DF recirculation. (a) Particles per milliliter of mAbA after 4 h recirculation of 100
mL of a 5 mg/mL solution in 10 mM histidine, 150 mM NaCl, pH 6.0, with various combinations of feed flow rate and TMP (n = 1). (b) Comparing
the effects of recirculation (with stirring) and stirring alone on protein particle formation (n = 3, mean ± SE). In both cases, particles were
counted using microflow imaging.
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Figure 2. Effects of solution conditions on stirring-induced particle formation in 3 mL vials. (a) Time course of stirring-induced particle
formation of 5mg/mL mAbA in 10 mM histidine, pH 6.0, with various concentrations of NaCl (n = 6, mean ± SE). (b) Particle formation after 1h
stirring in 10 mM histidine, pH 6.0, with or without 150 mM NaCl and with a range of PS80 concentrations (n = 3, mean ± SE).
the recirculation experiment could be because of particle trap-
ping by the UF/DF membrane. This result suggests that the
mechanism of particle formation is not specific to peristaltic
pumping, interactions with the membrane, or the flow envi-
ronment across the membrane. Although stirring itself is a
complex stress and could lead to particle formation via shear
stress or interfacial interactions, this finding focuses our atten-
tion away from stresses specific to the rest of the UF/DF system
and toward general agitation stresses of the kind experienced
in stirring. In particular, these results suggest that pump-
specific stresses, impurities leaching into the product stream
because of repeated pump–tubing interactions, shear stresses
experienced in the UF/DF membrane flow channel, and inter-
actions between the protein and membrane or tubing surfaces
are not the dominant factors causing UF/DF-induced particle
formation. Of the four original hypotheses, this finding leaves
shear stress and interfacial interactions as the remaining
possibilities.
On the basis of the relationship between UF/DF-induced
particle formation and stirring-induced particle formation, so-
lution conditions were varied in small-scale stirring exper-
iments in vials as a way to understand the factors gov-
erning stirring-induced particle formation. Figure 2a shows
that decreasing the NaCl concentration from 150 to 0 mM
NaCl reduces particle formation over 1 h of stirring in
vials. These results agree with previous findings from mAb
A demonstrating that low ionic strength allowed for elec-
trostatic repulsion, reducing turbidity and increasing vis-
cosity at high concentrations.28 Note that this reduction in
particle formation is only observed at very low NaCl concentra-
tions. Figure 2b demonstrates the effect of interfacial protec-
tion on stirring-induced particle formation through the addition
of polysorbate 80 (PS80). Adding PS80 to high salt solutions
achieves a partial reduction in particle formation, whereas com-
bining PS80 and low salt leads to a near-complete inhibition of
stirring-induced particle formation.
Together, these results suggest that stirring accelerates the
transport of proteins to and from interfaces that then induce
particle formation. Typical agitation experiments involving
shaking or rotation continuously deform the air–liquid inter-
face, leading to turnover in the population of proteins at the in-
terface, inducing aggregation and particle formation. Although
our stirring experiments were designed to avoid surface de-
formation, the fluid flow similarly refreshes the population of
proteins at both air–liquid and liquid–solid interfaces. PS80
presumably reduces particle formation by competing with the
protein for particle-inducing interfaces, but this protection
against particle formation is far greater in low-conductivity so-
lutions. The fact that PS80 reduces agitation-induced particle
formation argues against a shear-driven pathway, as experi-
ments with PS80 involve the same shear stress to the protein.
Low NaCl concentrations likely protect against particle for-
mation by enabling electrostatic repulsion between protein
molecules,28 but it remains unclear how this repulsion reduces
interfacially driven particle formation. This effect could indi-
cate that in addition to interfacial interactions, stirring pro-
motes protein–protein collisions in the bulk, and that low ionic
strength reduces the efficacy of these collisions in forming par-
ticles. Alternatively, the electrostatic protein–protein repulsion
at low NaCl concentrations could affect protein-interface in-
teractions in one of the two ways: low NaCl could reduce the
propensity of the protein to adsorb to the interface, or it could
reduce the propensity of proteins at the interface to form parti-
cles. These possibilities are addressed in part by the biophysical
characterization reported later in the manuscript, but further
experiments should be conducted to better understand this phe-
nomenon.
The results thus far suggest that UF/DF-induced particle
formation can be thought of as a particular form of the general
category of “agitation” stresses. To clarify this point, pumping
and UF/DF recirculation experiments were conducted under
the same solution conditions as tested for stirring. As seen in
Figure 3a, peristaltic pumping of mAb A solutions leads to rapid
particle formation, and both pumping-induced (Fig. 3a) and
UF/DF-induced (Fig. 3b) particle formation are reduced at low
NaCl concentration or in the presence of PS80. The consistency
of these effects among stirring, pumping, and UF/DF strength-
ens the argument that particle formation during UF/DF is not
driven by factors specific to the membrane or pump such as
the membrane surface, the membrane geometry or flow pat-
tern, pump-induced cavitation, or pump-driven introduction of
impurities. Instead, this process is driven by the transport of
protein molecules to and from particle-inducing interfaces that
can result from stirring, pumping, or recirculation in the UF/DF
unit. The greater relative effect of PS80 addition to a high salt
solution in the recirculation experiment as compared with the
stirring experiment suggests that interfacial interactions are
the predominant factor in actual UF/DF operation.
Additional proteins (see Table 1) were studied to determine
the generality of the phenomena observed here. mAb B was
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Figure 3. Effects of NaCl and PS80 on particle formation in pumping and recirculation experiments. (a) Pumping of 5mg/mL mAbA in 10
mM histidine, pH 6.0, with 1 foot of STA-PURE R© tubing at the pump head connected with 3feet of platinum-cured silicone tubing (n = 1). (b)
Recirculation of 100 mL of 5mg/mL mAbA at constant volume in a UF/DF unit with STA-PURE R© tubing at the pump head (n = 3).
Table 1. Molecular Properties
Molecule Isotype pI MW (kDa)
mAbA IgG1 7.87–8.25 148
mAbB IgG1 8.98–9.03 148
mAbC IgG1 8.6–9.1 145
mAbD IgG2 8.36–8.47 147
lysozyme 11.35 14
ovalbumin 4.54 44
"-chymotrypsinogen 8.97 26
subjected to the same stresses (stirring, pumping, and recircu-
lation) under the same solution conditions (high/low NaCl, +/−
PS80) as mAb A, whereas mAb C and D and three additional
proteins were subjected to stirring. As shown for the stirring
data in Figure 4, although different proteins yield different to-
tal particle numbers, the trends are consistent. All four mAbs
and two out of three non-mAbs tested here form particles in re-
sponse to stirring (lysozyme is omitted from the graph as <2000
particles/mL were formed in each condition), and both mAb A
and B form particles upon pumping and UF/DF recirculation.
Further, all of these proteins form fewer particles at lower NaCl
concentrations and in the presence of PS80. Although these re-
sults do not ensure that all proteins will exhibit the same be-
havior, they suggest that UF/DF-induced particle formation re-
sults from interfacial interactions rather than molecule-specific
characteristics. Furthermore, although different mAbs exhibit
different propensities to form particles in response to these
stresses, the same mitigation strategies are likely to benefit a
wide range of molecules.
These results suggest that interfacial interactions are re-
sponsible for UF/DF-induced particle formation, and that
adding PS80 to the process stream and conducting UF/DF at
low conductivity are potential mitigation strategies to prevent
particle formation. Before testing these strategies in bench-
scale concentration and diafiltration runs, we investigated
whether other additives could also be used to protect against
UF/DF-induced particle formation. This additive screening had
the particular goal of identifying non-micelle forming addi-
tives to protect against particle formation, as micelle forma-
tion of PS80 and other surfactants with micelle sizes greater
than the molecular weight cutoff of the membrane would lead
to concentration of the additive along with the protein and
thus difficulty in controlling the additive concentration. Thus,
we tested hydroxypropyl-$-cyclodextrin (HP$CD) based on a
previous study demonstrating protection against agitation-
induced protein aggregation29; the hydrophobic amino acids
Figure 4. Comparison with additional proteins. (a) Particle formation after 1h stirring of 5mg/mL protein solutions in vials in 10 mM histidine,
pH 6.0, with or without 150 mM NaCl and 0.03% PS80 (n = 3, mean ± SE). "-Chymotrypsinogen experiments were performed at 1 mg/mL
because of the low solubility of this molecule, and ovalbumin was tested at pH 7.0 because of its pI. (b) Pumping-induced particle formation of
5mg/mL mAbA and B in 10 mM histidine, pH 6.0, 150 mM NaCl (experiments were also performed in 0 mM NaCl and 0.03% PS80 but are not
plotted as all datapoints were <103). (c) Particle formation of 5mg/mL mAbA and B solutions in 10 mM histidine, pH 6.0, in UF/DF recirculation
with stirring (n = 1).
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Figure 5. Testing additives as protectants against UF/DF-induced particle formation. (a) Particle formation after 1h stirring in 3mL vials for
5mg/mL mAbA in 10 mM histidine, pH 6.0, with or without 150 mM NaCl and the additives indicated in the legend (n = 3, mean ± SE). (b)
UF/DF recirculation-induced particle formation of 5mg/mL mAbA in 10 mM histidine, 150 mm NaCl, pH 6.0, at 50 mL/min feed flow and 15psi
TMP (n = 1).
isoleucine, leucine, and phenylalanine30; and the known pro-
tein stabilizerarginine.31
These additives were tested for their ability to protect
against stirring-induced (Fig. 5a) and UF/DF-induced parti-
cle formation (Fig. 5b). Some of the hydrophobic amino acids
yielded marginal reductions in stirring-induced particle forma-
tion, whereas arginine and HP$CD provided excellent protec-
tion against agitation-induced particle formation. All of the ad-
ditives tested here led to some reduction in particle formation,
with HP$CD as the most effective. To understand the mecha-
nisms by which these additives affect protein particle forma-
tion, we measured the conformational and colloidal stability of
mAb A in these conditions, as well as the surface tension of the
solutions (Table 2).
Table 2 reports the Tm1 and Tm2 values obtained from DSC
as measures of the conformational stability of mAb A, and the
colloidal stability is captured by the kD parameter determined
from DLS experiments, with more negative kD values repre-
senting more attractive protein–protein interactions. Compar-
ing the data for mAb A between high and low [NaCl] conditions,
decreasing [NaCl] leads to two effects: conformational stabiliza-
tion, as demonstrated by the lack of a Tm1 corresponding to the
unfolding of the CH2 domain, and an improvement in colloidal
stability. No change in surface tension was observed, suggesting
that rather than reducing the amount of protein that adsorbs
to the air–water interface, low NaCl concentrations reduce the
ability of the interface to induce particle formation. mAb B ex-
hibits a greater colloidal stability than mAb A at both high
and low [NaCl], which could explain the lower level of particle
formation observed for mAb B. These results, along with those
for all four amino acids, suggest that agitation-induced protein
particle formation is related to colloidal stability in the absence
of interfacial protection, with less attractive protein–protein
interactions leading to a lower level of particle formation.
Although PS80 is sometimes suggested to affect protein sta-
bility through direct PS80–protein interactions in solution, in
this case we observe no difference in the protein’s conforma-
tional or colloidal stability in the presence of PS80. The signifi-
cantly lower surface tension in the presence of PS80 (p < 0.001)
demonstrates that PS80 coats the air–liquid interface, prevent-
ing protein-interface adsorption because of its higher surface
activity. Although HP$CD has been proposed to protect against
agitation-induced aggregation and particle formation by pro-
viding interfacial protection,29 we observe no effect of HP$CD
on any of the three parameters measured here. This observa-
tion is in agreement with recent findings that HP$CD does not
prevent protein-interface adsorption in the same way as PS80,
and the mechanism by which it protects against interfacially
induced particle formation remains under investigation.32
Next, the potential mitigation strategies were investigated
in bench-scale concentration and diafiltration experiments at
low conductivity or with PS80, HP$CD, or arginine added to the
Table 2. Effects of Solution Additives on mAb Conformational and Colloidal Stability and Surface Tension
mAb [NaCl] (mM) Additive Tm1, Tm2 (◦C)a kDb Surface Tension (mN/M)c
mAbA 150 – 67.6, 78.7 −17.4 54.8 ± 0.5
mAbA 0 – No Tm1, 78.2 −13.1 54.8 ± 0.4
mAbB 150 – 66.5, 83.3 −7.42 55.2 ± 0.2
mAbB 0 – 68.7, 85.4 43.86 54.4 ± 0.4
mAbA 150 0.03% PS80 67.8, 78.6 −16.4 36.7 ± 0.4
mAbA 150 10 mM HP$CD 68.4, 78.9 −20.0 53.5 ± 1.4
mAbA 150 150 mM Arg 66.8, 78.3 −10.3 54.7 ± 0.3
mAbA 150 80 mM Phe 66.2, 77.3 −14.8 45.0 ± 0.2
mAbA 150 80 mM Ile 68.1, 79.0 −14.3 55.3 ± 1.0
mAbA 150 80 mM Leu 68.3, 78.7 −11.0 54.5 ± 0.2
All samples were prepared in 10 mM histidine, pH 6.0.
aMelting temperatures indicating conformational stability were determined using DSC (n = 2, mean).
bkD captures colloidal stability and was determined as the slope/intercept of the D versus [mAb] graph generated from DLS data (n = 3, with six wells measured
in each experiment).
cSurface tensions are reported for 5mg/mL mAb solutions (n = 3, mean ± SE).
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Figure 6. Testing mitigation strategies for UF/DF-induced particle formation. (a) Particle counts for the final concentrated material. Approxi-
mately 5 g of mAbA was concentrated from 5 to 120mg/mL with six diavolumes at 40mg/mL. (b) Filterability of the final concentrated solution
adjusted to 100mg/mL (both n = 3, mean ± SE).
UF/DF product stream. As we expected PS80 to be concentrated
along with the protein because of its propensity for micelle for-
mation, 0.0016% PS80 was added so that the final concentra-
tion (measured as 0.015%) would remain below the formulation
concentration of 0.03%. The results in Figure 6a demonstrate
that low NaCl concentration, the addition of PS80, and the ad-
dition of HP$CD all led to statistically significant decreases
in protein particle formation during UF/DF. PS80 reduced
in-process particle formation by about 15-fold, whereas reduc-
ing NaCl concentration and adding HP$CD led to roughly four-
fold reductions. Further, as noted in a previous publication,28
electrostatic repulsion at low NaCl concentrations leads to a
high viscosity at high protein concentrations, making the final
concentration difficult at low NaCl. Arginine exhibited very lit-
tle effect on particle formation in UF/DF. Experiments at 150
and 500 mM arginine revealed no change in the level of in-
process particle formation, and these results are omitted from
Figure 6 as n = 1. This finding highlights the importance of the
interface in particle formation in UF/DF: although PS80 and
potentially HP$CD provide protection against interfacially in-
duced particle formation, arginine is thought to protect against
protein–protein interactions by binding to the protein surface,
leading to a crowding effect and increasing the energetic bar-
rier to self-association.33 In this case, arginine improves the
colloidal stability of the mAb (Table 2). As the effect of argi-
nine is believed to rely on arginine–protein binding, the argi-
nine to protein concentration ratio may affect its ability to sup-
press aggregation. Thus, at the low protein concentration used
in the stirring and recirculation experiments (5 mg/mL), 150
mM arginine may induce sufficient crowding to significantly
reduce particle formation, even in the absence of interfacial
protection. In actual UF/DF operation, however, the arginine
concentration remains the same while the protein concentra-
tion increases, potentially decreasing the ability of this addi-
tive to protect against particle formation because of the lower
arginine to protein ratio. In contrast, interfacial protectants
are not dependent on the additive-to-protein concentration ra-
tio, and thus remain effective throughout the concentration
experiment.
Although particles formed during UF/DF can be filtered
away, in some cases without significant effects on yield or post-
filtration stability, limiting particle formation during UF/DF
operation has the additional benefit of improving the filterabil-
ity of the concentrated product as shown in Figure 6b. Of the
three conditions with reduced levels of particle formation in
Figure 6a, two (0 mM NaCl and 0.03% PS80) exhibited notable
improvements in filterability. Although HP$CD led to a five-
fold reduction in particle formation, it only led to a two-fold
increase in filterability, compared with a 10-fold increase in
the presence of polysorbate. Thus, these results demonstrate
that controlling particle formation can significantly improve
the ease of processing downstream of the UF/DF step.
The results of this study suggest two strategies to pre-
vent protein particle formation during UF/DF: adding PS80
or HP$CD. As most processes have UF/DF as the final step,
additives to prevent particle formation must be acceptable as
formulation excipients. Polysorbates are common biopharma-
ceutical excipients but will be concentrated during UF/DF, ne-
cessitating careful planning and in-process concentration test-
ing and adjustment to ensure that the final polysorbate level is
within the target range. HP$CD overcomes this limitation as
it does not form micelles and can be added to the UF/DF step
at the desired formulation concentration. Although it is less
common than PS80, HP$CD has been approved as a formula-
tion excipient for small molecule drugs34 and has been studied
as a biopharmaceutical formulation excipient, suggesting that
this may be a viable strategy to prevent in-process particle
formation.
CONCLUSIONS
Although the strength of this study’s conclusions are limited
by the small number of proteins examined and the apparent
complexity of this phenomenon, this work improves our un-
derstanding of the mechanism of protein particle formation
in UF/DF operation and offers several mitigation strategies
that can be used to limit particle formation during produc-
tion operations. Particle formation during UF/DF operation is
shown to be driven by the transport of protein molecules to
and from hydrophobic interfaces that then induce particle for-
mation. Adding a surface-active molecule to the product pool
successfully mitigates particle formation during UF/DF oper-
ation, and solution conditions that improve colloidal stability
also reduce the level of particle formation. Polysorbates are
good candidates as interfacial protectants as they are common
biopharmaceutical formulation excipients, but their concentra-
tion cannot be easily controlled because of their propensity for
micelle formation. HP$CD presents the opportunity to limit
Callahan, Stanley, and Li, JOURNAL OF PHARMACEUTICAL SCIENCES 103:862–869, 2014 DOI 10.1002/jps.23861
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particle formation while maintaining control over the excipient
concentration.
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